Results from a recent survey of 400 women’s healthcare professionals* are cause for concern

56% prescribe fluconazole for VVC during one or more trimesters of pregnancy14

But recent data and guidelines suggest they shouldn’t:

  • Major 2016 study associates increased miscarriage risk with low-dose fluconazole7
  • FDA Drug Safety Communication advises caution8
  • CDC Guidelines say only topical azoles, applied for 7 days, should be used during pregnancy2

See details

MONISTAT® 7 meets CDC Guidelines for pregnant patients. Fluconazole does not.

75% prescribe fluconazole first-line for patients with diabetes15

Yet it poses concerns for many diabetic women:

  • Drug interaction risks with widely used hypoglycemics and statins11,12,19
  • CDC Guidelines suggest fluconazole NOT be used first-line for non-albicans VVC, common in diabetic women2

See details

MONISTAT® 7 is appropriate for diabetic patients

43% said they prescribe >1 fluconazole pill for uncomplicated VVC more than they did 3-5 years ago20

Dramatic dose increases suggest diminished efficacy:

  • ~60% of patients get more than 1 tablet as initial treatment5
  • Fluconazole resistance has risen steadily, but miconazole resistance has remained low and unchanged3

See details

Recommend MONISTAT® (miconazole) first-line

70% have suspected microbial resistance in patients unresponsive to a fluconazole 150 mg dose21

Fluconazole does not treat some prevalent Candida species:

  • Nearly 30% of infections are now caused by non-albicans species18
  • Fluconazole does not treat C. glabrata, the most prevalent non-albicans species16

MONISTAT® treats the yeast species that cause >98% of vaginal yeast infections16,18

See species comparison chart

*OB/GYNs (n=200); NPs, PAs (n=200)
†First-line: more than other common treatments